Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25256296 | 0.94 | P2RY6 (0.59) | P2RY6MEN1THRBRECQLBLM | |
| SCHEMBL14088823 | 0.92 | MEN1 (0.56) | P2RY6MEN1THRBRECQLBLM | |
| SCHEMBL14958553 | 0.88 | MEN1 (0.56) | P2RY6MEN1THRBRECQLBLM | |
| Tetramethylrhodamine SCHEMBL30354573 | 0.86 | P2RY6 (0.62) | P2RY6MEN1THRBRECQLBLM | |
| SCHEMBL21878583 | 0.83 | P2RY6 (0.67) | P2RY6MEN1THRBRECQLBLM | |
| Tetramethylrhodamine SCHEMBL13815486 | 0.83 | P2RY6 (0.67) | P2RY6MEN1THRBRECQLBLM | |
| Tetramethylrhodamine SCHEMBL29838750 | 0.83 | P2RY6 (0.67) | P2RY6MEN1THRBRECQLBLM | |
| SCHEMBL20200017 | 0.82 | P2RY6 (0.66) | P2RY6MEN1THRBRECQLBLM | |
| Tetramethylrhodamine SCHEMBL30091907 | 0.82 | P2RY6 (0.66) | P2RY6MEN1THRBRECQLBLM | |
| Tetramethylrhodamine SCHEMBL29587824 | 0.82 | P2RY6 (0.66) | P2RY6MEN1THRBRECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12631612-B2 | Fluorescent dye molecules for tracer applications in subterranean formations | SAUDI ARABIAN OIL COMPANY (SA) | 2026-05-19 | — | — | US | disclosed |
| US-12543952-B2 | Imaging system and method for fluorescence guided surgery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-10 | — | — | US | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12440821-B2 | Method for tracing subterranean formations with oil-soluble organic molecular tracers and extracting them of from oil phases | SAUDI ARABIAN OIL COMPANY (SA) | 2025-10-14 | — | — | US | disclosed |
| US-20250237670-A1 | MULTI-STAGE SAMPLE RECOVERY SYSTEM | XCELLA BIOSCIENCES INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-12286574-B2 | Manipulating hydrophilicity of conventional dye molecules for tracer applications | SAUDI ARABIAN OIL COMPANY (SA) | 2025-04-29 | — | — | US | disclosed |
| EP-4525935-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum (DE) | 2025-03-26 | — | — | EP | disclosed |
| US-12228584-B2 | Multi-stage sample recovery system | xCella Biosciences, Inc. (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2025027479-A1 | METHODS OF MULTIPLEXED ANALYTE CHARACTERIZATION | WATERS TECHNOLOGIES CORPORATION (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2023004189-A1 | METHOD FOR DETECTING ALLELES ASSOCIATED WITH KERATOCONUS | AVELLINO LAB USA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-11525160-B2 | Methods for multiplex detection of alleles associated with ophthalmic conditions | AVELLINO LAB USA, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11473081-B2 | Methods and systems for screening using microcapillary arrays | xCella Biosciences, Inc. (US) | 2022-10-18 | — | — | US | disclosed |
| CN-108220406-B | Method for detecting nucleic acid sequence variants | 生物概念股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-110268108-B | Methods and systems for screening using microcapillary arrays | 埃克切拉生物科学公司 | 2022-09-06 | — | — | CN | disclosed |
| EP-4041311-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | Alume Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022155385-A1 | METHODS AND COMPOSITIONS FOR VISUALIZING A URETER IN A SURGICAL PROCEDURE | ALUME BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20220162594-A1 | METHODS AND SYSTEMS FOR SCREENING USING MICROCAPILLARY ARRAYS | xCella Biosciences, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12631612-B2 | Fluorescent dye molecules for tracer applications in subterranean formations | CD99, TST, TDO2 | P2RY6 2743/4885MEN1 3536/4885THRB 439/4885 |
| US-20250360236-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | KLK3, FOLH1, MPI | P2RY6 1801/4885MEN1 77/4885THRB 2091/4885 |
| US-12543952-B2 | Imaging system and method for fluorescence guided surgery | FAU, ZKSCAN2, IWS1 | P2RY6 3097/4885MEN1 2060/4885THRB 2420/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | P2RY6 4033/4885MEN1 1105/4885THRB 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.